Yanli Zhuang

Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy

Markos Leggas, Masashi Adachi, George L. Scheffer et al. · Molecular and Cellular Biology · 2004 · 414 citations · Full text

Medicine, Oncology, Pharmacology +17

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

Philip J. Mease, Proton Rahman, Alice B. Gottlieb et al. · The Lancet · 2020 · 344 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +9

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

Atul Deodhar, Philip Helliwell, Wolf‐­Henning Boehncke et al. · The Lancet · 2020 · 322 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Atul Deodhar, Alice B. Gottlieb, Wolf‐­Henning Boehncke et al. · The Lancet · 2018 · 184 citations

Medicine, Clinical Sciences, Pharmacotherapy +7

Gefitinib Modulates the Function of Multiple ATP-Binding Cassette Transporters <i>In vivo</i>

Markos Leggas, John C. Panetta, Yanli Zhuang et al. · Cancer Research · 2006 · 154 citations

Medicine, Pharmacokinetics, Pharmacology +17